Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical impr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Arthritis Rheumatol
Autores principales: Deakin, Claire T., Campanilho‐Marques, Raquel, Simou, Stefania, Moraitis, Elena, Wedderburn, Lucy R., Pullenayegum, Eleanor, Pilkington, Clarissa A.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pediatric Rheumatology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947636/
https://ncbi.nlm.nih.gov/pubmed/29342499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40418
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares